Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience

CONTEXT: Nimotuzumab is the only anti-epidermal growth factor receptor monoclonal antibody which can be safely added to concurrent chemoradiotherapy (CRT) to improve efficacy in the management of unresectable, locally advanced squamous cell carcinoma of head and neck (LA-SCCHN). However, the evidenc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:South Asian J Cancer
Hauptverfasser: Rawat, Shyamji, Tandan, Hemu, Patel, Sanandan, Chaudhari, Sameer
Format: Artigo
Sprache:Inglês
Veröffentlicht: Medknow Publications & Media Pvt Ltd 2019
Schlagworte:
ORIGINAL ARTICLE: Head and Neck Cancers
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6348788/
https://ncbi.nlm.nih.gov/pubmed/30766856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/sajc.sajc_76_18
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge